Congenital Gerbode defects, consisting of a deficiency in the membranous septum causing left ventricle-to-right atrium shunting, are rarely hemodynamically significant. Here, we present the case of a neonate with a large unrestrictive Gerbode defect, patent foramen ovale, patent ductus arteriosus, and pulmonary valve insufficiency resulting in a circular intracardiac shunt and cardiogenic shock. The patient was managed with venoarterial extracorporeal membrane oxygenation followed by neonatal Gerbode defect repair. After repair, the patient had an uncomplicated postoperative course. To our knowledge, a neonatal congenital Gerbode defect resulting in cardiogenic shock is exceedingly rare.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11708502 | PMC |
| http://dx.doi.org/10.1016/j.atssr.2023.05.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neonatal Gerbode Defect Resulting in Cardiogenic Shock.
Ann Thorac Surg Short Rep
September 2023
Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Congenital Gerbode defects, consisting of a deficiency in the membranous septum causing left ventricle-to-right atrium shunting, are rarely hemodynamically significant. Here, we present the case of a neonate with a large unrestrictive Gerbode defect, patent foramen ovale, patent ductus arteriosus, and pulmonary valve insufficiency resulting in a circular intracardiac shunt and cardiogenic shock. The patient was managed with venoarterial extracorporeal membrane oxygenation followed by neonatal Gerbode defect repair.
View Article and Find Full Text PDFCircular Shunt: A Loop Not to Be Ignored.
J Cardiothorac Vasc Anesth
December 2024
Department of Cardiothoracic Surgery, National Heart Center, Royal Hospital, Muscat, Oman.
A circular shunt, initially described by Shone et al. in 1962, refers to abnormal blood recirculation through complete intracardiac or intra- and extracardiac communications, bypassing the capillary beds. This pathophysiological condition is most commonly associated with complex congenital heart defects, such as Ebstein's malformation, pulmonary atresia, Gerbode defect, and so on.
View Article and Find Full Text PDFHemolytic anemia after percutaneous coronary intervention (PCI): A case report.
Heliyon
November 2024
Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, PR China.
Background: In clinical practice, intravascular hemolysis is not common after interventional cardiovascular procedures. Although diagnostic and treatment techniques have developed, with the increasing importance placed on people's own health and the popularity of cardiovascular intervention, there have been occasional reports of hemolysis after different cardiovascular interventions, mainly including cardiac pacemaker implantation, atrial-fibrillation radiofrequency ablation, transcatheter aortic-valve implantation (TAVI), transcatheter mitral valve replacement (TMVR) and percutaneous repair of Gerbode defect and percutaneous coronary intervention (PCI) with Impella. However, so far, there have been no relevant reports on postoperative hemolysis after percutaneous coronary intervention (PCI).
View Article and Find Full Text PDFA case report of Ebstein's anomaly-Gerbode defect dyad: is there room for another anomaly in the same patient?
Eur Heart J Case Rep
September 2024
Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 5th Dept. of Internal Medicine, Medical Clinic No.1, 40006 Cluj-Napoca, Romania.
Article Synopsis
- - Ebstein's anomaly is a rare heart condition where the tricuspid valve is positioned unusually low in the heart and is often linked to other heart defects.
- - A case involving a 50-something man with Ebstein's anomaly and a rare combination with a septal defect (Gerbode defect) was discovered through MRI, along with an unusual origin of his right coronary artery.
- - Despite having several congenital issues, the patient had few symptoms until developing atrial flutter, which was successfully treated with catheter ablation, highlighting the importance of advanced imaging for diagnosis.
Off-label uses of the Amplatzer Piccolo Occluder in children with congenital and acquired heart diseases.
Future Cardiol
October 2024
Department of Pediatrics, Division of Cardiology, University of Tennessee Health Science Center, Le Bonheur Children's Hospital, Memphis, TN, USA.
The Amplatzer Piccolo Occluder (APO) is approved for patent ductus arteriosus (PDA) occlusion in infants weighing >700 g but could offer versatility to treat other lesions. Retrospective review of children in whom APO was utilized for defects other than PDA between January 2022 and June 2023. The APO was used in nine patients; three for ventricular septal defects, four with coronary fistulas, one for a ventricular pseudoaneurysm and one where APO deployed within a fenestration of a previously placed Amplatzer Septal Occluder.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!